Related Experiment Videos
pVHL's kryptonite: E2-EPF UCP.
1Department of Laboratory Medicine and Pathobiology, University of Toronto, 1 King's College Circle, Toronto, Ontario M5S 1A8, Canada. michael.ohh@utoronto.ca
Cancer Cell
|August 15, 2006
Summary
E2-EPF ubiquitin carrier protein (UCP) targets the von Hippel-Lindau (VHL) tumor suppressor protein. This finding reveals a potential role for UCP in cancer development through the VHL-HIF pathway.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- E2-EPF ubiquitin carrier protein (UCP) is an E2 enzyme family member.
- UCP catalyzes ubiquitin ligation to proteins for proteasomal degradation.
- UCP overexpression in cancers suggests oncogenic involvement, but its physiologic target was unknown.
Purpose of the Study:
- To identify a bona fide substrate of UCP.
- To elucidate the role of UCP in cancer development.
Main Methods:
- The study identified UCP's substrate using biochemical assays.
- Investigated the pVHL-HIF pathway's interaction with UCP.
Main Results:
- Identified the von Hippel-Lindau (VHL) tumor suppressor protein as a bona fide substrate of UCP.
- Demonstrated that VHL targets the alpha subunit of hypoxia-inducible factor (HIF) for destruction.
- Established a potential pVHL-HIF pathway-dependent role for UCP in cancer development.
Conclusions:
- UCP directly interacts with and ubiquitinates the VHL tumor suppressor protein.
- UCP's role in cancer may be mediated by its regulation of the VHL-HIF pathway.
- This discovery opens new avenues for understanding UCP's function in oncogenesis.